<?xml version="1.0"?>
<case>
<name>Memcor Australia Pty Ltd v G E Betzdearborn Canada Company (Corrigendum dated 21 May 2009) [2009] FCA 507 (20 May 2009)</name>
<AustLII>http://www.austlii.edu.au/au/cases/cth/FCA/2009/507.html</AustLII>
<citphrases>
<citphrase id="cp0.0" type=cited from="[2009] FCAFC 18">intellectual property</citphrase>
<citphrase id="cp0.1" type=cited from="[2009] FCAFC 18">patents</citphrase>
<citphrase id="cp0.2" type=cited from="[2009] FCAFC 18">claims, construction of</citphrase>
<citphrase id="cp0.3" type=cited from="[2009] FCAFC 18">need for practical understanding of claims in context of relevant field of art</citphrase>
<citphrase id="cp0.4" type=cited from="[2009] FCAFC 18">whether purely grammatical approach sufficient. intellectual property</citphrase>
<citphrase id="cp0.5" type=cited from="[2009] FCAFC 18">patents</citphrase>
<citphrase id="cp0.6" type=cited from="[2009] FCAFC 18">validity</citphrase>
<citphrase id="cp0.7" type=cited from="[2009] FCAFC 18">obviousness</citphrase>
<citphrase id="cp0.8" type=cited from="[2009] FCAFC 18">evidence of inventor</citphrase>
<citphrase id="cp0.9" type=cited from="[2009] FCAFC 18">whether entitled to special weight</citphrase>
<citphrase id="cp0.10" type=cited from="[2009] FCAFC 18">expert evidence that solution generally along the lines of apparatus claimed to be inventive would have been readily apparent to someone skilled in the art</citphrase>
<citphrase id="cp0.11" type=cited from="[2009] FCAFC 18">expert supplied with patent before expressing opinion</citphrase>
<citphrase id="cp0.12" type=cited from="[2009] FCAFC 18">whether value of evidence diminished because expert informed of problem and solution</citphrase>
<citphrase id="cp0.13" type=cited from="[2009] FCAFC 18">whether broad identification of generic solution meant invention itself was obvious.</citphrase>
<citphrase id="cp1.0" type=cited from="[2008] FCAFC 178">patents</citphrase>
<citphrase id="cp1.1" type=cited from="[2008] FCAFC 178">invalidity</citphrase>
<citphrase id="cp1.2" type=cited from="[2008] FCAFC 178">lack of novelty</citphrase>
<citphrase id="cp1.3" type=cited from="[2008] FCAFC 178">road safety barriers</citphrase>
<citphrase id="cp1.4" type=cited from="[2008] FCAFC 178">infringement claim upheld by primary judge</citphrase>
<citphrase id="cp1.5" type=cited from="[2008] FCAFC 178">cross claim for invalidity by virtue of lack of novelty upheld</citphrase>
<citphrase id="cp1.6" type=cited from="[2008] FCAFC 178">appeal against declaration of invalidity</citphrase>
<citphrase id="cp1.7" type=cited from="[2008] FCAFC 178">construction of claims</citphrase>
<citphrase id="cp1.8" type=cited from="[2008] FCAFC 178">whether guard member mounted on side walls of at least two barrier elements</citphrase>
<citphrase id="cp1.9" type=cited from="[2008] FCAFC 178">no requirement that guard member be secured by a physical connection through side wall</citphrase>
<citphrase id="cp1.10" type=cited from="[2008] FCAFC 178">composite beam effect asserted by patentee not a feature required to be disclosed by us patent in order that it anticipate australian patent.</citphrase>
<citphrase id="cp2.0" type=cited from="[2005] FCAFC 251">intellectual property</citphrase>
<citphrase id="cp2.1" type=cited from="[2005] FCAFC 251">patents</citphrase>
<citphrase id="cp2.2" type=cited from="[2005] FCAFC 251">infringement of letters patent</citphrase>
<citphrase id="cp2.3" type=cited from="[2005] FCAFC 251">construction of patent</citphrase>
<citphrase id="cp2.4" type=cited from="[2005] FCAFC 251">letters patent</citphrase>
<citphrase id="cp2.5" type=cited from="[2005] FCAFC 251">registered design</citphrase>
<citphrase id="cp2.6" type=cited from="[2005] FCAFC 251">obvious imitation of a registered design</citphrase>
<citphrase id="cp2.7" type=cited from="[2005] FCAFC 251">fraudulent imitation</citphrase>
<citphrase id="cp2.8" type=cited from="[2005] FCAFC 251">prior art.</citphrase>
<citphrase id="cp3.0" type=cited from="[2005] FCAFC 224">patents</citphrase>
<citphrase id="cp3.1" type=cited from="[2005] FCAFC 224">validity</citphrase>
<citphrase id="cp3.2" type=cited from="[2005] FCAFC 224">construction</citphrase>
<citphrase id="cp3.3" type=cited from="[2005] FCAFC 224">lack of inventive step</citphrase>
<citphrase id="cp3.4" type=cited from="[2005] FCAFC 224">novelty</citphrase>
<citphrase id="cp3.5" type=cited from="[2005] FCAFC 224">fair basis</citphrase>
<citphrase id="cp3.6" type=cited from="[2005] FCAFC 224">sufficiency of description of invention</citphrase>
<citphrase id="cp3.7" type=cited from="[2005] FCAFC 224">disclosure of best method of invention</citphrase>
<citphrase id="cp3.8" type=cited from="[2005] FCAFC 224">date of assessment</citphrase>
<citphrase id="cp3.9" type=cited from="[2005] FCAFC 224">false suggestion</citphrase>
<citphrase id="cp3.10" type=cited from="[2005] FCAFC 224">patent for treatment of erectile dysfunction</citphrase>
<citphrase id="cp3.11" type=cited from="[2005] FCAFC 224">common general knowledge at priority date</citphrase>
<citphrase id="cp3.12" type=cited from="[2005] FCAFC 224">relevant prior art</citphrase>
<citphrase id="cp3.13" type=cited from="[2005] FCAFC 224">use of evidence of overseas witnesses</citphrase>
<citphrase id="cp4.0" type=cited from="[2005] FCA 805">patent</citphrase>
<citphrase id="cp4.1" type=cited from="[2005] FCA 805">appeal from dismissal of opposition by commissioner of patents</citphrase>
<citphrase id="cp4.2" type=cited from="[2005] FCA 805">burden of proof where extensive evidence</citphrase>
<citphrase id="cp4.3" type=cited from="[2005] FCA 805">whether obviousness evidence assessed on balance of probabilities</citphrase>
<citphrase id="cp4.4" type=cited from="[2005] FCA 805">multi-hull seagoing vessels</citphrase>
<citphrase id="cp4.5" type=cited from="[2005] FCA 805">novelty</citphrase>
<citphrase id="cp4.6" type=cited from="[2005] FCA 805">anticipation</citphrase>
<citphrase id="cp4.7" type=cited from="[2005] FCA 805">essential and inessential integers</citphrase>
<citphrase id="cp4.8" type=cited from="[2005] FCA 805">"substantial portion" in claim understood in context of whole specification</citphrase>
<citphrase id="cp4.9" type=cited from="[2005] FCA 805">evidence on normal meaning of terms not relevant</citphrase>
<citphrase id="cp4.10" type=cited from="[2005] FCA 805">precise mathematical parameters in claims</citphrase>
<citphrase id="cp4.11" type=cited from="[2005] FCA 805">whether differences said to be not material to performance are included in mathematical criteria</citphrase>
<citphrase id="cp4.12" type=cited from="[2005] FCA 805">whether made essential</citphrase>
<citphrase id="cp4.13" type=cited from="[2005] FCA 805">not a case for purposive construction</citphrase>
<citphrase id="cp4.14" type=cited from="[2005] FCA 805">mechanical equivalence of inessential not essential integers</citphrase>
<citphrase id="cp4.15" type=cited from="[2005] FCA 805">whether claims permit a 2% variation said to be within operational functions and of no practical significance</citphrase>
<citphrase id="cp4.16" type=cited from="[2005] FCA 805">hindsight in evidence of disclosure of prior publication</citphrase>
<citphrase id="cp4.17" type=cited from="[2005] FCA 805">fact that witness aware of patent specified not of itself sufficient to disregard evidence</citphrase>
<citphrase id="cp4.18" type=cited from="[2005] FCA 805">lack of inventive step and obviousness</citphrase>
<citphrase id="cp4.19" type=cited from="[2005] FCA 805">assertion that prior art vessels essentially achieved solution although not within claimed parameters</citphrase>
<citphrase id="cp4.20" type=cited from="[2005] FCA 805">hindsight</citphrase>
<citphrase id="cp4.21" type=cited from="[2005] FCA 805">manner of manufacture</citphrase>
<citphrase id="cp4.22" type=cited from="[2005] FCA 805">whether claims limited to exemplified embodiments</citphrase>
<citphrase id="cp4.23" type=cited from="[2005] FCA 805">utility</citphrase>
<citphrase id="cp4.24" type=cited from="[2005] FCA 805">embodiments within the claims that are not useful and would not be considered</citphrase>
<citphrase id="cp4.25" type=cited from="[2005] FCA 805">proper construction of claims</citphrase>
<citphrase id="cp4.26" type=cited from="[2005] FCA 805">whether all embodiments fulfil the promised advantages of the invention</citphrase>
<citphrase id="cp4.27" type=cited from="[2005] FCA 805">fair basis</citphrase>
<citphrase id="cp4.28" type=cited from="[2005] FCA 805">clarity</citphrase>
<citphrase id="cp6.0" type=cited from="[2001] HCA 8">kimberly-clark australia pty ltd v arico trading international pty ltd  patents</citphrase>
<citphrase id="cp6.1" type=cited from="[2001] HCA 8">validity</citphrase>
<citphrase id="cp6.2" type=cited from="[2001] HCA 8">revocation</citphrase>
<citphrase id="cp6.3" type=cited from="[2001] HCA 8">whether invention sufficiently described</citphrase>
<citphrase id="cp6.4" type=cited from="[2001] HCA 8">whether complete specification includes claims</citphrase>
<citphrase id="cp6.5" type=cited from="[2001] HCA 8">whether sufficiency determined by reference to skilled addressee.</citphrase>
<citphrase id="cp10.0" type=cited from="[1991] FCA 434">designs</citphrase>
<citphrase id="cp10.1" type=cited from="[1991] FCA 434">electrically powered wheelchairs for the disabled</citphrase>
<citphrase id="cp10.2" type=cited from="[1991] FCA 434">infringement</citphrase>
<citphrase id="cp10.3" type=cited from="[1991] FCA 434">statement of monopoly sought protection for the design as a whole</citphrase>
<citphrase id="cp10.4" type=cited from="[1991] FCA 434">obvious imitation</citphrase>
<citphrase id="cp10.5" type=cited from="[1991] FCA 434">fraudulent imitation.  patents</citphrase>
<citphrase id="cp10.6" type=cited from="[1991] FCA 434">petty patent</citphrase>
<citphrase id="cp10.7" type=cited from="[1991] FCA 434">infringement</citphrase>
<citphrase id="cp10.8" type=cited from="[1991] FCA 434">revocation</citphrase>
<citphrase id="cp10.9" type=cited from="[1991] FCA 434">obviousness or want of subject matter.</citphrase>
<citphrase id="cp12.0" type=citing from="[2011] FCA 282">patents</citphrase>
<citphrase id="cp12.1" type=citing from="[2011] FCA 282">construction of claims</citphrase>
<citphrase id="cp12.2" type=citing from="[2011] FCA 282">clarity</citphrase>
<citphrase id="cp12.3" type=citing from="[2011] FCA 282">claim narrower than specification</citphrase>
<citphrase id="cp12.4" type=citing from="[2011] FCA 282">meaning of "an enzyme"</citphrase>
<citphrase id="cp12.5" type=citing from="[2011] FCA 282">meaning of "generated from"</citphrase>
<citphrase id="cp12.6" type=citing from="[2011] FCA 282">meaning of "functional ingredient"</citphrase>
<citphrase id="cp12.7" type=citing from="[2011] FCA 282">meaning of "inactivating or denaturing the enzyme"</citphrase>
<citphrase id="cp12.8" type=citing from="[2011] FCA 282">construction difficult</citphrase>
<citphrase id="cp12.9" type=citing from="[2011] FCA 282">not render claim invalid</citphrase>
<citphrase id="cp12.10" type=citing from="[2011] FCA 282">clear construction available  patents</citphrase>
<citphrase id="cp12.11" type=citing from="[2011] FCA 282">construction of claims</citphrase>
<citphrase id="cp12.12" type=citing from="[2011] FCA 282">based on language of independent claim, second constituent does not include water</citphrase>
<citphrase id="cp12.13" type=citing from="[2011] FCA 282">water stated as a second constituent in specification and dependent claim</citphrase>
<citphrase id="cp12.14" type=citing from="[2011] FCA 282">patentee says reference to water is a "mistake"</citphrase>
<citphrase id="cp12.15" type=citing from="[2011] FCA 282">whether water can be constituent of independent claim  patents</citphrase>
<citphrase id="cp12.16" type=citing from="[2011] FCA 282">construction of claims</citphrase>
<citphrase id="cp12.17" type=citing from="[2011] FCA 282">limitation by result</citphrase>
<citphrase id="cp12.18" type=citing from="[2011] FCA 282">inactivated or denatured enzyme</citphrase>
<citphrase id="cp12.19" type=citing from="[2011] FCA 282">standard of inactivation</citphrase>
<citphrase id="cp12.20" type=citing from="[2011] FCA 282">workable standard</citphrase>
<citphrase id="cp12.21" type=citing from="[2011] FCA 282">no significant or material amount of active enzyme  patents</citphrase>
<citphrase id="cp12.22" type=citing from="[2011] FCA 282">invention</citphrase>
<citphrase id="cp12.23" type=citing from="[2011] FCA 282">relevance of invention disclosure statement to construction of claims</citphrase>
<citphrase id="cp12.24" type=citing from="[2011] FCA 282">relevance of invention disclosure statement to inventive step</citphrase>
<citphrase id="cp12.25" type=citing from="[2011] FCA 282">relevance of invention disclosure statement to characterisation of invention  patents</citphrase>
<citphrase id="cp12.26" type=citing from="[2011] FCA 282">infringement</citphrase>
<citphrase id="cp12.27" type=citing from="[2011] FCA 282">whether infringement by supply of product pursuant to patents act 1990 (cth) s 117</citphrase>
<citphrase id="cp12.28" type=citing from="[2011] FCA 282">ss 117(2)(a) , (b) and (c)</citphrase>
<citphrase id="cp12.29" type=citing from="[2011] FCA 282">whether indirect infringement as joint tortfeasor  patents</citphrase>
<citphrase id="cp12.30" type=citing from="[2011] FCA 282">validity</citphrase>
<citphrase id="cp12.31" type=citing from="[2011] FCA 282">novelty</citphrase>
<citphrase id="cp12.32" type=citing from="[2011] FCA 282">understanding of skilled reader following directions in prior publication</citphrase>
<citphrase id="cp12.33" type=citing from="[2011] FCA 282">whether following directions would disclose the process</citphrase>
<citphrase id="cp12.34" type=citing from="[2011] FCA 282">whether following directions would disclose the results of the process being essential integers of the claims</citphrase>
<citphrase id="cp12.35" type=citing from="[2011] FCA 282">whether there was disclosure of products of the process as functional ingredients</citphrase>
<citphrase id="cp12.36" type=citing from="[2011] FCA 282">whether information in prior publication discloses the integers of the claimed process  patents</citphrase>
<citphrase id="cp12.37" type=citing from="[2011] FCA 282">validity</citphrase>
<citphrase id="cp12.38" type=citing from="[2011] FCA 282">novelty</citphrase>
<citphrase id="cp12.39" type=citing from="[2011] FCA 282">anticipation by use</citphrase>
<citphrase id="cp12.40" type=citing from="[2011] FCA 282">whether anticipation by "inevitable result"</citphrase>
<citphrase id="cp12.41" type=citing from="[2011] FCA 282">inherent activity of enzyme disclosed</citphrase>
<citphrase id="cp12.42" type=citing from="[2011] FCA 282">whether clear and unmistakable directions to the process of the claims where claims include specified result and meaning of prior information</citphrase>
<citphrase id="cp12.43" type=citing from="[2011] FCA 282">whether, where disclosure is incomplete in prior publication, completion by following directions must be publicly available prior to priority date</citphrase>
<citphrase id="cp12.44" type=citing from="[2011] FCA 282">whether anticipation by "inevitable result" where resulting information not available prior to priority date</citphrase>
<citphrase id="cp12.45" type=citing from="[2011] FCA 282">enzyme and clone deposited</citphrase>
<citphrase id="cp12.46" type=citing from="[2011] FCA 282">hypothetical use</citphrase>
<citphrase id="cp12.47" type=citing from="[2011] FCA 282">whether enzyme could in fact have been obtained for use prior to priority date</citphrase>
<citphrase id="cp12.48" type=citing from="[2011] FCA 282">whether information equating to the result was disclosed prior to the priority date</citphrase>
<citphrase id="cp12.49" type=citing from="[2011] FCA 282">whether skilled addressee would know that result of use of enzyme in prior art document was claimed process</citphrase>
<citphrase id="cp12.50" type=citing from="[2011] FCA 282">whether necessary for anticipation by inevitable result for directions in prior art document to have been able to be followed by skilled addressee before priority date of the patent  patents</citphrase>
<citphrase id="cp12.51" type=citing from="[2011] FCA 282">validity</citphrase>
<citphrase id="cp12.52" type=citing from="[2011] FCA 282">novelty</citphrase>
<citphrase id="cp12.53" type=citing from="[2011] FCA 282">"whole of contents" citation pursuant to paragraph (b)(ii) of "prior art base" definition</citphrase>
<citphrase id="cp12.54" type=citing from="[2011] FCA 282">identification of "information" under paragraph (b)(ii) of "prior art base" definition</citphrase>
<citphrase id="cp12.55" type=citing from="[2011] FCA 282">drafting of notional claims</citphrase>
<citphrase id="cp12.56" type=citing from="[2011] FCA 282">whether permissible to draft notional claims with hindsight</citphrase>
<citphrase id="cp12.57" type=citing from="[2011] FCA 282">notional claims alter words used in consistory clause</citphrase>
<citphrase id="cp12.58" type=citing from="[2011] FCA 282">whether notional claims fairly based</citphrase>
<citphrase id="cp12.59" type=citing from="[2011] FCA 282">whether notional claims contain information that anticipates the claims of the patent  patents</citphrase>
<citphrase id="cp12.60" type=citing from="[2011] FCA 282">validity</citphrase>
<citphrase id="cp12.61" type=citing from="[2011] FCA 282">obviousness</citphrase>
<citphrase id="cp12.62" type=citing from="[2011] FCA 282">inventive step</citphrase>
<citphrase id="cp12.63" type=citing from="[2011] FCA 282">"problem and solution" approach</citphrase>
<citphrase id="cp12.64" type=citing from="[2011] FCA 282">whether material in specification is part of problem or solution</citphrase>
<citphrase id="cp12.65" type=citing from="[2011] FCA 282">whether necessary for lack of inventive step to prove skilled addressee would try each integer of process</citphrase>
<citphrase id="cp12.66" type=citing from="[2011] FCA 282">whether reference in specification to enzyme from unpublished specification made enzyme part of common general knowledge  patents</citphrase>
<citphrase id="cp12.67" type=citing from="[2011] FCA 282">manner of manufacture</citphrase>
<citphrase id="cp12.68" type=citing from="[2011] FCA 282">whether lack of manner of manufacture apparent on face of specification</citphrase>
<citphrase id="cp12.69" type=citing from="[2011] FCA 282">whether new substance, new characteristic of a known substance, new use or new method</citphrase>
<citphrase id="cp12.70" type=citing from="[2011] FCA 282">cross-reference to unpublished priority application</citphrase>
<citphrase id="cp12.71" type=citing from="[2011] FCA 282">statement of incorporation by reference</citphrase>
<citphrase id="cp12.72" type=citing from="[2011] FCA 282">whether whole of unpublished priority application can be taken into consideration</citphrase>
<citphrase id="cp12.73" type=citing from="[2011] FCA 282">whether reference to nature and characteristics of enzyme incorporated the whole of the prior document</citphrase>
<citphrase id="cp12.74" type=citing from="[2011] FCA 282">whether disclosures of unpublished priority application describe invention</citphrase>
</citphrases>
<citances>
<sentence id="cs0" from="[2011] FCA 282">If the enzyme is a lipase, it is a hydrolase which catalyses a hydrolysis reaction, in the presence of water. The passage relied on by Novozymes is not a definition but a description of what may occur. Even if it were a definition, the context of the claims must prevail ( Memcor Australia Pty Ltd v GE Betzdearborn Canada Company [2009] FCA 507 ; (2009) 81 IPR 315 at [60] , upheld on appeal ). First, the incorporation of that definition would render the second use of "generated" in the claim redundant. Secondly, it introduces incorrect terminology if it means that the functional ingredient is "generated from" water.</sentence>
<sentence id="cs1" from="[2010] APO 19">The opponent had also indicated that the ambit of the term "particulate matter" was very broad as one could not have recourse to the specification to determine its meaning (as per Jagot J in Memcor Australia Pty Ltd v GE Betzdearborn Canada Company [2009] FCA 507 ; (2009) 81 IPR 315 at 334[62] and 335[64]). However, in view of the fact that Professor Leslie has indicated that the membrane filtration generally refers to the use of microporous membranes, the particulate matter being filtered would lie in the range suitable for that purpose.
  The opponent noted that claim 1 of the Parent required that the multiplicity of hollow fiber membranes be "unconfined in a shell of a module" whereas in claims 23 to 37 of the divisional the only requirement is that there be a "skein of hollow fiber filtering membranes immersed in the substrate". They submitted that "...in the same way that Jagot J *was not prepared to incorporate the definition of 'vertical skein' into the claims of the Parent, the glossary may not be used to incorporate the definition of 'skein' and thereby import a limitation on the meaning of the claims 23 to 37 of the Divisional. Instead the term skein should be understood in the plain English sense, as a bundle of fibres. Those fibres may, or may not, be 'unconfined in a shell of a module'" *( Memcor Australia Pty Ltd v GE Betzdearborn Canada Company [2009] FCA 507 (20 May 2009))
 </sentence>
</citances>
<legistitles>
<title id="l0">PATENTS ACT 1990 </title>
<title id="l1">PATENTS ACT 1990 - SECT 79 Rights of patentee if extension granted after patent expires</title>
<title id="l2">PATENTS ACT 1990 - SECT 79B Divisional applications prior to grant of patent</title>
<title id="l3">FEDERAL COURT RULES </title>
<title id="l4">PATENTS REGULATIONS 1991 </title>
</legistitles>
</case>